Divestiture Possible For Merck’s Animal Health, Consumer Units; Januvia’s Sales Slide
This article was originally published in The Pink Sheet Daily
Executive Summary
The performance of Merck’s diabetes franchise came under scrutiny by analysts on an earnings call Oct 28, after the company reported sales of its number one drug fell 5% in the third quarter year on year. Top executives came closer than ever to saying they are inclined to divest non-core businesses, including animal health.